AbbVie Beat on Skyrizi-So Why Did the Stock Sell Off?

AbbVie beat estimates, but the market focused on the guide cut

AbbVie delivered a strong second quarter, yet the stock still sold off because investors were focused less on the beat and more on the company's lower full-year outlook. Even after reporting $16.990 billion in second-quarter net revenues and adjusted diluted EPS of $3.65, shares fell more than 4% in premarket trading.

The immediate reason was straightforward: AbbVie trimmed its 2026 adjusted EPS outlook to $13.87 to $14.07 from $13.91 to $14.11, a 2026 EPS hit of 14 cents from planned Apogee deal. That did not break the operating story, but it gave investors a reason to question how much headroom remains after acquisition-related costs.

Skyrizi and Rinvoq are still carrying the story

The quarter itself was not weak. AbbVie posted adjusted EPS up 22.9%, immunology revenue up 15.1%, and neuroscience revenue up 20.3%. Skyrizi and Rinvoq continued to anchor growth, which confirms that AbbVie is still executing its transition away from Humira.

But the market is no longer satisfied with a simple beat. It is asking whether that growth is durable enough to absorb acquisition drag and still produce clean earnings power. That is why this quarter became a repricing debate rather than an automatic positive.

Growth quality is now the real question

A clean quarterly print was only part of the story. The more important issue is how much of AbbVie's earnings power comes from core franchise growth versus businesses and deals that still carry accounting or integration complexity.

That concern was reinforced by the quarter's unfavorable impact of $0.17 per share related to acquired IPR&D and milestones expense. The amount is not huge on its own, but it matters because it reminds investors that AbbVie is asking the market to look past expense items that can cloud the earnings signal.

The bull case is that AbbVie still has enough underlying momentum to fund the next phase of expansion. Management had previously lifted 2026 adjusted EPS guidance to $14.08 to $14.28. Even after the Apogee-related step-down, AbbVie still said it expects a 2026 EPS hit of 14 cents from planned Apogee deal, which bulls can frame as a manageable friction point if the core businesses keep compounding.

The bear case is that investors are getting less willing to look past that friction. AbbVie has spent more than $20 billion on acquisitions and plans another $10 billion over the next decade. After that level of spending, the market cares less about whether revenue beat and more about whether deal-making is improving returns or just adding complexity.

What would stabilize the stock

The next catalyst is not another headline beat by itself. It is evidence that acquired assets and newer franchise growth are producing cleaner earnings, not just larger revenues.

Signs that the stock could stabilize include:

• Cleaner guidance: future quarters where commentary needs fewer acquisition- or expense-related cushions.
• No repeat guide cuts: management keeps or expands the full-year view without another step-down tied to Apogee or similar items.
• Core growth carries the load: immunology and other key franchises keep advancing even after the Apogee-related earnings impact.
• Better signal quality: acquired IPR&D and milestone expense stop dominating the discussion around growth quality.

The cautious bull case would break here

A constructive view on AbbVie still makes sense if the operating story keeps improving. But that case weakens if the market decides the company is buying growth faster than it is buying clarity.

The clearest warning sign would be future quarters where revenue and EPS commentary still depend on deal- or expense-related cushions after the current acquisition is integrated. Another red flag would be operational cooling in the key franchises. If Skyrizi and Rinvoq lose pace while acquisition-related dilution keeps showing up, investors are likely to stop looking through the noise and reprice the strategy.